Amgen (AMGN) Declares $1.15 Quarterly Dividend; 2.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
Amgen (AMGN) PT Lowered to $193 at Morgan Stanley Following 3Q
October 26, 2017 9:25 AM EDTMorgan Stanley lowered its price target on Amgen (NASDAQ: AMGN) to $193.00 (from $196.00) while maintaining a Overweight rating following the company's 3Q release. Total revenues were slightly above ($5.77B vs. $5.74B cons), as were COGS (+$10M) and SG&A (+$20M), with R&D... More
Amgen (AMGN) Names Wanda Austin to Board
October 24, 2017 4:36 PM EDTAmgen (NASDAQ: AMGN) today announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee meetings. Dr. Austin will serve as a member of the Board's Audit Committee and the Corporate Responsibility and Compliance Committee. Following the appointment of Dr. Austin, the Board will comprise 14 directors, 13 of whom are... More
